Pear expects $22M in revenue this year, as it banks on growing adoption of digital therapeutics

In its first earnings report since it went public, Pear Therapeutics met its guidance for 2021. The company, which makes digital therapeutics for substance use and insomnia, merged with a special-purpose acquisition company (SPAC) in December. The company brought in $4.2 million in revenue for the year, above its $4 million guidance, and also beat milestones for the number of prescriptions and covered lives.